Buffer

Innovator ETFs Announces New Upside Cap Ranges for November Series of U.S. Equity Buffer ETFs

Monday, October 25, 2021 - 11:01pm

The November series of Innovator U.S. Equity Buffer ETFs ( BNOV ; PNOV ; UNOV ) currently have a remaining outcome period of less than one week.

Key Points: 
  • The November series of Innovator U.S. Equity Buffer ETFs ( BNOV ; PNOV ; UNOV ) currently have a remaining outcome period of less than one week.
  • Innovators Equity Buffer ETFs have traditionally used index-based options while the Defined Outcome Bond ETFs and Stacker ETFs have been constructed using fund-based options.
  • Innovators category-creating Defined Outcome ETF familyincludes Buffer ETFs, Stacker ETFs and Floor ETFs.
  • Innovators category-creating Defined Outcome ETF family includes Buffer ETFs, Floor ETFs, Stacker ETFs and the Accelerated ETFs.

Purigen Biosystems Enables Scientists to Extract and Purify Higher Yields of DNA from Fresh Frozen Tissue Samples

Tuesday, October 19, 2021 - 1:03pm

Purigen Biosystems, Inc. , a leading provider of next-generation technologies for extracting and purifying nucleic acids from biological samples, today announced the launch of the Ionic Tissue to Pure DNA Kit.

Key Points: 
  • Purigen Biosystems, Inc. , a leading provider of next-generation technologies for extracting and purifying nucleic acids from biological samples, today announced the launch of the Ionic Tissue to Pure DNA Kit.
  • The new kit allows users of the Ionic Purification System to extract increased yields of high-quality DNA from fresh frozen biological samples with a simple, automated workflow.
  • View the full release here: https://www.businesswire.com/news/home/20211019005342/en/
    Purigen Biosystems' automated Ionic Tissue to Pure DNA Kit recovers more than three times the amount of high-quality nucleic acid from limited samples compared to leading column-based products.
  • (Photo: Business Wire)
    The Ionic Tissue to Pure DNA Kit consistently provides more than three times higher DNA yields compared to leading column-based kits.

Movellus CEO Mo Faisal to Present at Linley Fall Processor Conference

Friday, October 15, 2021 - 1:22pm

SANTA CLARA, Calif., Oct. 15, 2021 /PRNewswire/ -- Movellus Inc., announced today that Mo Faisal, President and CEO of Movellus, will present at the Linley Fall Processor Conference.

Key Points: 
  • SANTA CLARA, Calif., Oct. 15, 2021 /PRNewswire/ -- Movellus Inc., announced today that Mo Faisal, President and CEO of Movellus, will present at the Linley Fall Processor Conference.
  • The conference will be held in-person on October 20-21 at the Hyatt Regency Hotel in Santa Clara, CA, followed by a virtual event on October 27-29, November 3-5 2021.
  • The Linley Conferences provide a unique opportunity to discover, inquire, and network with key providers of advanced technology products.
  • What: In his presentation, "60% of SoCs Lose 30-50% Performance Due to Clock Networks," Mr. Faisal will address three simple questions executives can ask to reveal inefficiencies.

ANGUS To Expand U.S. Manufacturing Capacity For TRIS AMINO™ Tromethamine Buffers

Thursday, October 14, 2021 - 2:00pm

BUFFALO GROVE, Ill., Oct. 14, 2021 /PRNewswire/ -- ANGUS Chemical Company ("ANGUS" or "Company"), a leading global manufacturer and marketer of specialty ingredients and consumables for biotechnology, pharmaceutical, consumer and industrial applications, today announced plans to expand U.S. production capacity for its complete portfolio of TRIS AMINO tromethamine buffers.

Key Points: 
  • BUFFALO GROVE, Ill., Oct. 14, 2021 /PRNewswire/ -- ANGUS Chemical Company ("ANGUS" or "Company"), a leading global manufacturer and marketer of specialty ingredients and consumables for biotechnology, pharmaceutical, consumer and industrial applications, today announced plans to expand U.S. production capacity for its complete portfolio of TRIS AMINO tromethamine buffers.
  • The planned expansion includes the addition of a fourth dedicated manufacturing line at ANGUS' existing facility in Sterlington, Louisiana, and will roughly double the Company's global TRIS AMINO buffer production capacity.
  • Today, the company produces high-purity, multi-compendial grades of TRIS AMINO products for the life sciences and personal care markets at its Sterlington and recently expanded Ibbenbren, Germany manufacturing facilities.
  • Between 2016 and 2021, ANGUS doubled TRIS AMINO production capacity.

Global Cell Therapy Consumables Market (2021 to 2031) - by Type of Consumable, Type of Cell Therapy, Scale of Operation, Type of End-User and Key Geographical Regions - ResearchAndMarkets.com

Tuesday, October 12, 2021 - 4:00pm

The "Cell Therapy Consumables Market by Type of Consumable, Type of Cell Therapy, Scale of Operation, Type of End-User and Key Geographical Regions: Industry Trends and Global Forecasts, 2021 - 2031" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cell Therapy Consumables Market by Type of Consumable, Type of Cell Therapy, Scale of Operation, Type of End-User and Key Geographical Regions: Industry Trends and Global Forecasts, 2021 - 2031" report has been added to ResearchAndMarkets.com's offering.
  • This report features an extensive study on the consumable providers within the cell therapy industry.
  • What is the current, global demand (kits, media and reagents) for cell therapy consumables in the manufacturing process?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Aceto Expands GMP Product Lines for Biopharmaceutical and Vaccine Manufacturing with Acquisition of A&C Bio Buffer

Tuesday, October 12, 2021 - 12:30pm
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20211012005100/en/
    Inside A&C Bio Buffer's manufacturing facility in Limerick, Ireland.
  • (Photo: Business Wire)
    A&C Bio Buffer is a natural add-on to our acquisition of A&C and aligns with our commitments to the biopharmaceutical space, said Gilles Cottier, Chief Executive Officer of Aceto.
  • A&C Bio Buffer enhances our growing European manufacturing footprint and commercial presence.
  • Services offered include GMP custom ingredient development, GMP custom manufacturing and GMP custom packaging.

ANGUS Appoints Biopharma Executive Julie O'Neill To Board Of Directors

Wednesday, October 6, 2021 - 2:00pm

BUFFALO GROVE, Ill., Oct. 6, 2021 /PRNewswire/ --ANGUS Chemical Company ("ANGUS" or "Company"), a leading global manufacturer and marketer of specialty ingredients for biotechnology, pharmaceutical, consumer and industrial applications, today announced the appointment of Julie O'Neill to the Company's Board of Directors.

Key Points: 
  • BUFFALO GROVE, Ill., Oct. 6, 2021 /PRNewswire/ --ANGUS Chemical Company ("ANGUS" or "Company"), a leading global manufacturer and marketer of specialty ingredients for biotechnology, pharmaceutical, consumer and industrial applications, today announced the appointment of Julie O'Neill to the Company's Board of Directors.
  • O'Neill is a results-driven biopharmaceutical executive, with more than two decades of leadership experience and currently serves on the board of several leading life sciences companies.
  • "We are thrilled to welcome Julie to our board.
  • "I am delighted to join the Board of Directors of ANGUS," said O'Neill.

Pacer ETFs Expands Structured Outcome Strategy ETFs With October Series

Friday, October 1, 2021 - 2:30pm

Pacer ETFs (Pacer), an ETF provider that offers strategy-driven, rules-based ETFs, announces the next addition to the Pacer Swan SOS ETF family with its October series.

Key Points: 
  • Pacer ETFs (Pacer), an ETF provider that offers strategy-driven, rules-based ETFs, announces the next addition to the Pacer Swan SOS ETF family with its October series.
  • The launch includes: Pacer Swan SOS Conservative (October) ETF (PSCQ), Pacer Swan SOS Moderate (October) ETF (PSMO) and Pacer Swan SOS Flex (October) ETF (PSFO).
  • Each ETF within the series comes with a varied structured outcome strategy, allowing investors to be deliberate in how they manage risk.
  • Pacer ETFs is focused on addressing investors needs through its six fund families, the Pacer Trendpilot Series, Pacer Cash Cows Index Series, Pacer Custom ETF Series, Pacer Leaders ETF Series, Pacer Factor ETF Series and Pacer Swan SOS ETF Series.

Innovator Completes International Equity Power Buffer ETF™ Suite and Adds to Accelerated ETFs™ Lineup with Listing of New October Defined Outcome ETFs™

Friday, October 1, 2021 - 2:23pm

The Defined Outcome ETFs are constructed using Cboe FLEX Options, offering exposure to markets rather than investing in them directly.

Key Points: 
  • The Defined Outcome ETFs are constructed using Cboe FLEX Options, offering exposure to markets rather than investing in them directly.
  • At the end of each Defined Outcome ETFs outcome period, the ETF will simply rebalance and reset, providing investors with new upside caps and a fresh buffer for those funds with a buffer strategy, over the next outcome period.
  • Innovators category-creating Defined Outcome ETF familyincludes Buffer ETFs, Stacker ETFs and Floor ETFs.
  • Innovators category-creating Defined Outcome ETF family includes Buffer ETFs, Floor ETFs, Stacker ETFs and the Accelerated ETFs.

Innovator Announces New Upside Caps for October and Quarterly Defined Outcome ETFs™

Friday, October 1, 2021 - 1:59pm

CHICAGO, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Innovator Capital Management, LLC (Innovator) today announced the new upside caps and return profiles for the October series of the sponsor’s Defined Outcome ETFs™, as well as the firm’s four ETFs with quarterly outcome periods that also rebalanced at the end of the month. The resetting ETFs span Innovator’s Defined Outcome ETF™ lineup, including Buffer ETFs™, Accelerated ETFs™, Stacker ETFs™ and Defined Outcome Bond ETFs™.

Key Points: 
  • The Stacker ETFs provide defined returns over the entire Outcome Period, not on a daily basis.
  • The shorter outcome period of the Quarterly outcome period Accelerated ETFs (XDSQ, XDQQ) means they will follow the reference asset (SPY or QQQ) more closely, but have lower starting caps than Accelerated ETFs with an annual outcome period.
  • Innovators category-creating Defined Outcome ETF familyincludes Buffer ETFs, Accelerated ETFs, Stacker ETFs and Floor ETFs.
  • Innovators category-creating Defined Outcome ETF family includes Buffer ETFs, Floor ETFs, Stacker ETFs and the Accelerated ETFs.